Chronic treatment with qiliqiangxin ameliorates aortic endothelial cell dysfunction in diabetic rats

Journal of Cardiovascular Pharmacology and Therapeutics

Volumn 20, Issue 2, 2015, Pages 230-240

  Chen, Fei ^a   Wu, Jia Le ^b   Fu, Guo Sheng ^c   Mou, Yun ^a,d   Hu, Shen Jiang ^a  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b The Xinhua Hospital   (China)

^c ZHEJIANG UNIVERSITY   (China)

^d ZHEJIANG UNIVERSITY   (China)

Author keywords

diabetes; endothelium; NOS; Qiliqiangxin; RAS

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BENAZEPRIL; CHINESE DRUG; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; QILIQIANGXIN; REACTIVE OXYGEN METABOLITE; SERINE; UNCLASSIFIED DRUG; ANGIOTENSIN 1 RECEPTOR; BENZAZEPINE DERIVATIVE; HERBACEOUS AGENT; STREPTOZOCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DRUG EFFECT; EC50; ECHOCARDIOGRAPHY; ENDOTHELIAL DYSFUNCTION; HEART FUNCTION; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART LEFT VENTRICLE PRESSURE; LONG TERM CARE; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; TREATMENT DURATION; VASCULAR RING; ANIMAL; BLOOD; DIABETES MELLITUS, EXPERIMENTAL; DRUG EFFECTS; ENDOTHELIUM CELL; HEART; PATHOPHYSIOLOGY; PHYSIOLOGY; SPRAGUE DAWLEY RAT; THORACIC AORTA; VASOCONSTRICTION;

ANIMALS; AORTA, THORACIC; BENZAZEPINES; DIABETES MELLITUS, EXPERIMENTAL; DRUGS, CHINESE HERBAL; ECHOCARDIOGRAPHY; ENDOTHELIAL CELLS; HEART; MALE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, ANGIOTENSIN, TYPE 1; STREPTOZOCIN; VASOCONSTRICTION;

EID: 84922666405     PISSN: 10742484     EISSN: 19404034     Source Type: Journal    
DOI: 10.1177/1074248414537705     Document Type: Article

References (43)

1. Nichols GA, Hillier TA, Erbey JR, Brown JB. Congestive heart failure in type 2 diabetes: prevalence, incidence, and risk factors. Diabetes Care. 2001 ; 24 (9). 1614-1619
2. Wells BJ, Roth R, Nowacki AS, et al. Prediction of morbidity and mortality in patients with type 2 diabetes. Peer J. 2013 ; 11: e87
3. Davignon J, Ganz P. Role of endothelial dysfunction in atherosclerosis. Circulation. 2004 ; 109: III27 - III32
4. Marti CN, Gheorghiade M, Kalogeropoulos AP, Georgiopoulou VV, Quyyumi AA, Butler J. Endothelial dysfunction, arterial stiffness, and heart failure. J Am Coll Cardiol. 2012 ; 60 (16). 1455-1469
5. Natali A, Ferrannini E. Endothelial dysfunction in type 2 diabetes. Diabetologia. 2012 ; 55 (6). 1559-1563
6. Van Craenenbroeck EM, Conraads VM. Mending injured endothelium in chronic heart failure: a new target for exercise training. Int J Cardiol. 2013 ; 166 (2). 310-314
7. Kapur NK, Wilson S, Yunis AA, et al. Reduced endoglin activity limits cardiac fibrosis and improves survival in heart failure. Circulation. 2012 ; 125 (22). 2728-2738
8. Tousoulis D, Charakida M, Stefanadis C. Inflammation and endothelial dysfunction as therapeutic targets in patients with heart failure. Int J Cardiol. 2005 ; 100 (3). 347-353
9. Katz SD, Hryniewicz K, Hriljac I, et al. Vascular endothelial dysfunction and mortality risk in patients with chronic heart failure. Circulation. 2005 ; 111 (3). 310-314
10. Chong AY, Blann AD, Patel J, Freestone B, Hughes E, Lip GY. Endothelial dysfunction and damage in congestive heart failure: relation of flow-mediated dilation to circulating endothelial cells, plasma indexes of endothelial damage, and brain natriuretic peptide. Circulation. 2004 ; 110 (13). 1794-1798
11. Kelland NF, Webb DJ. Clinical trials of endothelin antagonists in heart failure: a question of dose?. Exp Biol Med (Maywood). 2006 ; 231 (6). 696-699
12. Kirkby NS, Hadoke PW, Bagnall AJ, Webb DJ. The endothelin system as a therapeutic target in cardiovascular disease: great expectations or bleak house?. Br J Pharmac. 2008 ; 153 (6). 1105-1119
13. Liu W, Chen J, Xu T, et al. Qiliqiangxin improves cardiac function in spontaneously hypertensive rats through the inhibition of cardiac chymase. Am J Hypertens. 2012 ; 25 (2). 250-260
14. Wei Y, Liu X, Hou L, Che W, The E, Jhummon MV. Qiliqiangxin affects L type Ca(2+) current in the normal and hypertrophied rat heart. Evid Based Complement Alternat Med. 2012 ; 2012: 131830
15. Xiao H, Song Y, Li Y, Liao YH, Chen J. Qiliqiangxin regulates the balance between tumor necrosis factor-alpha and interleukin-10 and improves cardiac function in rats with myocardial infarction. Cell Immunol. 2009 ; 260 (1). 51-55
16. Zou Y, Lin L, Ye Y, et al. Qiliqiangxin inhibits the development of cardiac hypertrophy, remodeling, and dysfunction during 4 weeks of pressure overload in mice. J Cardiovasc Pharmacol. 2012 ; 59 (3). 268-280
17. Chen F, Chen B, Xiao FQ, et al. Autophagy protects against senescence and apoptosis via the RAS-mitochondria in high-glucose-induced endothelial cells. Cell Physiol Biochem. 2014 ; 33 (4). 1058-1074
18. Li X, Zhang J, Huang J, et al. Efficacy and Safety of Qili Qiangxin Capsules for Chronic Heart Failure Study Group. A multicenter, randomized, double-blind, parallel-group, placebo-controlled study of the effects of qili qiangxin capsules in patients with chronic heart failure. J Am Coll Cardiol. 2013 ; 62 (12). 1065-1072
19. Zhang J, Wei C, Wang H, et al. Protective effect of qiliqiangxin capsule on energy metabolism and myocardial mitochondria in pressure overload heart failure rats. Evid Based Complement Alternat Med. 2013 ; 378298: 2013
20. Fu GS, Huang H, Chen F, et al. Carvedilol ameliorates endothelial dysfunction in streptozotocin-induced diabetic rats. Eur J Pharmacol. 2007 ; 567 (3). 223-230
21. Imanishi T, Tsujioka H, Akasaka T. Endothelial progenitor cells dysfunction and senescence: contribution to oxidative stress. Curr Cardiol Rev. 2008 ; 4 (4). 275-286
22. Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature. 1980 ; 288 (5789). 373-376
23. Libby P, Aikawa M, Jain MK. Vascular endothelium and atherosclerosis. Handb Exp Pharmacol. 2006 ; (176 pt 2). 285-306
24. Rubanyi GM, Romero JC, Vanhoutte PM. Flow-induced release of endothelium-derived relaxing factor. Am J Physiol. 1986 ; 250 (6 pt 2). H1145 - H1149
25. Li H, Forstermann U. Nitric oxide in the pathogenesis of vascular disease. J Pathol. 2000 ; 190 (3). 244-254
26. Paneni F, Beckman JA, Creager MA, Cosentino F. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part I. Eur Heart J. 2013 ; 34 (31). 2436-2443
27. Agnoletti L, Curello S, Bachetti T, et al. Serum from patients with severe heart failure downregulates eNOS and is proapoptotic: role of tumor necrosis factor-alpha. Circulation. 1999 ; 100 (19). 1983-1991
28. Ikeda U, Shimada K. Nitric oxide and cardiac failure. Clin Cardiol. 1997 ; 20 (10). 837-841
29. Oyadomari S, Gotoh T, Aoyagi K, Araki E, Shichiri M, Mori M. Coinduction of endothelial nitric oxide synthase and arginine recycling enzymes in aorta of diabetic rats. Nitric Oxide. 2001 ; 5 (3). 252-260
30. Gao L, Huang W, Li J. NOX1 abet mesangial fibrogenesis via iNOS induction in diabetes. Mol Cell Biochem. 2013 ; 382 (1-2). 185-191
31. Jia J, Liu Y, Zhang X, Liu X, Qi J. Regulation of iNOS expression by NF-κB in human lens epithelial cells treated with high levels of glucose. Invest Ophthalmol Vis Sci. 2013 ; 54 (7). 5070-5077
32. Kim DH, Chung JH, Yoon JS, et al. Ginsenoside Rd inhibits the expressions of iNOS and COX-2 by suppressing NF-κB in LPS-stimulated RAW264.7 cells and mouse liver. J Ginseng Res. 2013 ; 37 (1). 54-63
33. Ropelle ER, Pauli JR, Cintra DE, et al. Targeted disruption of inducible nitric oxide synthase protects against aging, S-nitrosation, and insulin resistance in muscle of male mice. Diabetes. 2013 ; 62 (2). 466-470
34. Hare JM, Nguyen GC, Massaro AF, et al. Exhaled nitric oxide: a marker of pulmonary hemodynamics in heart failure. J Am Coll Cardiol. 2002 ; 40 (6). 1114-1119
35. Porrello ER, Amore AD, Curl CL, et al. Angiotensin II type 2 receptor antagonizes angiotensin II type 1 receptor-mediated cardiomyocyte autophagy. Hypertension. 2009 ; 53 (6). 1032-1040
36. Enzo RP, Lea MDD. Cardiomyocyte autophagy is regulated by angiotensin II type 1 and type 2 receptors. Autophagy. 2009 ; 5 (8). 1215-1216
37. Sandra D, Erika T, Marina Z, Lucia M. Sulfhydryl angiotensin-converting enzyme inhibitor promotes endothelial cell survival through nitric-oxide synthase, fibroblast growth factor-2, and telomerase cross-talk. J Pharmacol Exp Ther. 2010 ; 332 (3). 776-784
38. Blum A. Heart failure - new insights. Isr Med Assoc J. 2009 ; 11 (2). 105-111
39. Lip GY, Gibbs CR. Does heart failure confer a hypercoagulable state? Virchow's triad revisited. J Am Coll Cardiol. 1999 ; 33 (5). 1424-1426
40. Paskaloglu K, Sener G, Ayangolu-Dulger G. Melatonin treatment protects against diabetes-induced functional and biochemical changes in rat aorta and corpus cavernosum. Eur J Pharmacol. 2004 ; 499 (3). 345-354
41. Weber LP, MacLeod KM. Contractile responses of caudal arteries from diabetic rats to adrenergic nerve stimulation. J Vasc Res. 1994 ; 31 (1). 25-32
42. Xavier FE, Davel AP, Rossoni LV, et al. Time dependent hyperreactivity to phenylephrine in aorta from untreated diabetic rats: role of prostanoids and calcium mobilization. Vascul Pharmacol. 2003 ; 40 (1). 67-76
43. Ma FF, Lu FY, Feng SW, Li YX, Xiao WG. Influence of qiliqiangxin capsule on vascular endothelial function and heart function in patients with chronic heart failure. Mod Jour Integ Trad Chin West Med. 2008 ; 17 (17). 260-2603